Vanda Pharmaceuticals reports plans to price public offering of stock

Joint bookrunners Jefferies and Piper Jaffray to assist with offering

By Devika Patel

Knoxville, Tenn., Oct. 28 – Vanda Pharmaceuticals Inc. said it plans to price a public sale of common stock with a 30-day, 15% greenshoe, according to a prospectus supplement filed Tuesday with the Securities and Exchange Commission.

Jefferies LLC and Piper Jaffray & Co. are the joint bookrunners.

Proceeds will be used for sales and marketing expenditures, research and development and other general corporate purposes.

Vanda is a Rockville, Md.-based pharmaceuticals firm.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.